BIIB FY 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$9.8B+1.4% YoY

Gross Profit

$6.9B70.5% margin

Operating Income

$1.9B19.1% margin

Net Income

$1.3B13.2% margin

EPS (Diluted)

$8.83

Cash Flow

Operating Cash Flow

$2.2B

Free Cash Flow

$2.1B

Stock-Based Comp.

$291M

Balance Sheet

Total Assets

$29.4B

Total Liabilities

$11.2B

Stockholders' Equity

$18.3B

Cash & Equivalents

$3.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9.8B	$9.7B	+1.4%
Gross Profit	$6.9B	$7.4B	-6.1%
Operating Income	$1.9B	$2.5B	-24.6%
Net Income	$1.3B	$1.6B	-20.8%